First Peptide Drug Candidate Hits Two 'Undruggable' Pancreatic Cancer Targets at Once

KH-1 was identified through integrated virtual screening combining pharmacophore screening and molecular docking. Binding affinity was confirmed by microscale thermophoresis (MST) assays. Anti-cancer activity was tested in human pancreatic cancer cell lines measuring proliferation, invasion, migration, apoptosis (flow cytometry), and cell cycle arrest. In vivo efficacy was evaluated in a mouse xenograft tumor model, with organ toxicity assessed.

KRAS G12D is mutated in ~40% of pancreatic cancers and was long considered 'undruggable.' HDAC is a downstream signal that KRAS uses to promote tumor growth. Hitting both targets with a single peptide molecule could be more effective than targeting either alone, and the lack of organ toxicity in mice is encouraging for a disease that has a 5-year survival rate below 13%.

KRAS has been the holy grail of cancer drug targets — mutated in ~25% of all cancers and historically impossible to drug. Recent breakthroughs with sotorasib and adagrasib (targeting KRAS G12C) opened the door, but G12D mutations (more common in pancreatic cancer) remain harder to target. This peptide approach offers a fundamentally different strategy: using a peptide's larger binding surface to engage KRAS while simultaneously hitting a cooperating target (HDAC), potentially addressing resistance mechanisms that single-target drugs face.

Mouse xenograft models don't fully recapitulate human pancreatic cancer biology. No human data exists. The peptide's pharmacokinetics (half-life, bioavailability, metabolism) are not discussed. Pancreatic cancer's dense stroma may limit drug penetration in actual patients. Long-term toxicity is not assessed. Comparison to existing KRAS inhibitors or HDAC inhibitors is not provided.